

Evolution of CLL treatment “ from chemoimmunotherapy

Nature Reviews Clinical Oncology

15, 510-527

DOI: [10.1038/s41571-018-0037-8](https://doi.org/10.1038/s41571-018-0037-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 130.	6.9	25
2	Biclonal <i>IGHV</i> λ 4 hairy cell leukemia variant and CLL – successful treatment with ibrutinib and venetoclax. <i>American Journal of Hematology</i> , 2018, 93, 1568-1569.	2.0	24
3	Inactivation of Prostaglandin E2 as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 606.	1.3	12
4	Chronic lymphocytic leukaemia: from genetics to treatment. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 684-701.	12.5	154
5	Long non-coding RNA GAS5 regulates human B lymphocytic leukaemia tumourigenesis and metastasis by sponging miR-222. <i>Cancer Biomarkers</i> , 2019, 26, 385-392.	0.8	20
6	Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis. <i>Chemotherapy</i> , 2019, 64, 155-162.	0.8	0
7	The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling. <i>Frontiers in Immunology</i> , 2019, 10, 2455.	2.2	4
8	Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Targeted Oncology</i> , 2019, 14, 493-504.	1.7	6
9	Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2019, 9, 75.	2.8	43
10	Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005–2015 show improved survival over time. <i>European Journal of Haematology</i> , 2019, 103, 190-199.	1.1	2
11	Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984469.	1.1	3
12	Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2019, 8, 3131-3141.	1.3	10
13	Catalytic asymmetric acetalization of carboxylic acids for access to chiral phthalidyl ester prodrugs. <i>Nature Communications</i> , 2019, 10, 1675.	5.8	37
14	Molecular Players in Hematologic Tumor Cell Trafficking. <i>Frontiers in Immunology</i> , 2019, 10, 156.	2.2	40
15	Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib. <i>Clinical Cancer Research</i> , 2019, 25, 2372-2374.	3.2	0
16	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1340-1346.	2.0	7
17	Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2056-2068.	0.6	14
18	Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 418-427.	1.0	8

#	ARTICLE	IF	CITATIONS
19	The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 287-298.	3.3	39
20	Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. <i>Future Oncology</i> , 2019, 15, 579-589.	1.1	23
21	Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth. <i>International Journal of Molecular Sciences</i> , 2019, 20, 292.	1.8	10
22	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 1011-1019.	0.6	168
23	Blood and Guts: Diarrhea from Colonic Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Digestive Diseases and Sciences</i> , 2019, 64, 345-348.	1.1	1
24	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020, 34, 787-798.	3.3	321
25	Percutaneous coronary intervention and in-hospital outcomes in patients with leukemia: a nationwide analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 53-63.	0.7	20
26	PI3K-p110 β contributes to antibody responses by macrophages in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 451-461.	3.3	8
27	Selective inhibition of PI3K δ affects survival and proliferation of chronic lymphocytic leukemia B cells. <i>Leukemia and Lymphoma</i> , 2020, 61, 455-459.	0.6	1
28	The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. <i>Leukemia</i> , 2020, 34, 1588-1598.	3.3	18
29	Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 31-38.	1.0	5
30	Antihistamines are synergistic with Bruton's tyrosine kinase inhibitor ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells. <i>Leukemia Research</i> , 2020, 96, 106423.	0.4	5
31	The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 885-894.	1.0	2
32	Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. <i>European Journal of Haematology</i> , 2020, 105, 646-654.	1.1	34
33	Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse. <i>Biomarker Research</i> , 2020, 8, 72.	2.8	19
34	Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 130-137.	0.3	3
35	Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4877-4892.	1.0	19
36	Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. <i>Pharmaceutics</i> , 2020, 12, 520.	2.0	16

#	ARTICLE	IF	CITATIONS
37	Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. <i>Cancers</i> , 2020, 12, 282.	1.7	22
38	Management strategies and clinical outcomes of acute myocardial infarction in leukaemia patients: Nationwide insights from United States hospitalisations. <i>International Journal of Clinical Practice</i> , 2020, 74, e13476.	0.8	9
39	Oxidation Impacts the Intracellular Signaling Machinery in Hematological Disorders. <i>Antioxidants</i> , 2020, 9, 353.	2.2	6
40	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. <i>Cancers</i> , 2020, 12, 894.	1.7	22
41	Significance of Selective Protein Degradation in the Development of Novel Targeted Drugs and Its Implications in Cancer Therapy. <i>Advanced Therapeutics</i> , 2020, 3, 1900210.	1.6	2
42	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?. <i>International Journal of Hematology</i> , 2020, 111, 642-656.	0.7	1
43	mTOR inhibitor use in head and neck squamous cell carcinoma: A meta-analysis on survival, tumor response, and toxicity. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 243-255.	0.6	14
44	Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. <i>Haematologica</i> , 2021, 106, 968-977.	1.7	26
45	Apoptotic effect of berberine via Bcl-2, ROR1 and mir-21 in patients with chronic lymphocytic leukemia. <i>Phytotherapy Research</i> , 2021, 35, 2025-2033.	2.8	12
46	Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2021, 148, 419-428.	2.3	42
47	Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2021, 192, 333-342.	1.2	5
48	In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia. <i>Oncology Letters</i> , 2021, 21, 285.	0.8	4
49	Endogenous Stimulatable Nanomedicine for Immune Theranostics for Cancer. <i>Advanced Functional Materials</i> , 2021, 31, 2100386.	7.8	36
50	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 637186.	1.3	17
51	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. <i>Diagnostics</i> , 2021, 11, 853.	1.3	15
52	Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia. <i>Advances in Oncology</i> , 2021, 1, 249-262.	0.1	1
53	Chronic lymphocytic leukemia and the skin: implications for the dermatologist. <i>International Journal of Dermatology</i> , 2022, 61, 519-531.	0.5	9
54	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	0.6	30

#	ARTICLE	IF	CITATIONS
55	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6665.	1.8	11
56	Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 3856.	1.7	12
57	TAp63 and BCL2 expression are co-affected by cell-extrinsic signals in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-4.	0.6	1
58	MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. <i>Journal of Hematology and Oncology</i> , 2021, 14, 121.	6.9	72
59	Lymphoid NeXt-Generation Sequencing (LYNX) Panel. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 959-974.	1.2	11
60	Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence. <i>Journal of Modern Oncology</i> , 2021, 23, 332-338.	0.1	0
61	The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. <i>Current Opinion in Oncology</i> , 2021, 33, 670-680.	1.1	6
62	Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells. <i>Cancers</i> , 2021, 13, 4557.	1.7	12
63	Combined ibrutinib and venetoclax treatment vs single agents in the <i>TCL1</i> mouse model of chronic lymphocytic leukemia. <i>Blood Advances</i> , 2021, 5, 5410-5414.	2.5	20
64	Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 325-334.	0.9	6
65	Rare B-Cell Non-Hodgkinâ€™s Lymphomas in Childhood and Adolescence. , 2019, , 239-247.		0
66	Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. <i>Hematological Oncology</i> , 2022, 40, 129-159.	0.8	4
67	Gene Expression Profiling Predicts Sensitivity of Chronic Lymphocytic Leukemia Cells to Dasatinib. <i>HemaSphere</i> , 2021, 5, e514.	1.2	0
68	Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL). <i>Diagnostics</i> , 2021, 11, 2041.	1.3	2
69	Clinical Perspectives for Leukemia Treatment During Pregnancy. , 2021, , 23-48.		0
70	Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial. <i>Investigational New Drugs</i> , 2022, 40, 349.	1.2	2
71	First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i><i>versus</i></i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. <i>Haematologica</i> , 2022, 107, 2108-2120.	1.7	53
72	Delivery strategies in treatments of leukemia. <i>Chemical Society Reviews</i> , 2022, 51, 2121-2144.	18.7	17

#	ARTICLE	IF	CITATIONS
74	Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review. Expert Review of Hematology, 2022, 15, 273-284.	1.0	2
75	Targeted Drug Delivery for Chronic Lymphocytic Leukemia. Pharmaceutical Research, 2022, 39, 441-461.	1.7	8
76	CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia. Leukemia and Lymphoma, 2022, 63, 1617-1623.	0.6	3
77	Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet Haematology, the, 2022, 9, e190-e199.	2.2	18
78	Kronik lenfositik ilařemide tedavi yaklařmalar: Gerçek yařam verisi. Mersin Üniversitesi Saęlık Bilimleri Dergisi, 0, , 50-55.	0.2	0
85	Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2022, 12, .	1.3	6
86	Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 818-828.	5.1	21
87	Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leukemia and Lymphoma, 2022, 63, 2765-2784.	0.6	1
88	The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study. Hematological Oncology, 2022, 40, 962-975.	0.8	2
89	Anti-tumor effect of berberine on chronic lymphocytic leukemia cells. , 2022, 39, .		1
90	Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Drug Design, Development and Therapy, 0, Volume 16, 3225-3239.	2.0	6
91	Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	2
92	CD160 receptor in CLL: Current state and future avenues. Frontiers in Immunology, 0, 13, .	2.2	4
93	Kinase inhibitor therapies for Chronic lymphocytic leukaemia (CLL): SYK, BTK and PI3K inhibitors. , 0, 19, 30-35.		0
94	Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia. Frontiers in Oncology, 0, 12, .	1.3	1
95	Expert consensus on the management of chronic lymphocytic leukaemia in Asia. Clinical and Experimental Medicine, 2023, 23, 2895-2907.	1.9	1
96	Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial intelligence-assisted workflow. Cytometry Part B - Clinical Cytometry, 0, , .	0.7	1
97	Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study. Frontiers in Oncology, 0, 13, .	1.3	1

#	ARTICLE	IF	CITATIONS
98	Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2023, 29, 420-430.	0.5	1
99	BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2529-2539.	2.0	3
100	Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
102	<i>Cancers hÃ©matologiques.</i> , 2023, , 221-228.		0
109	Zanubrutinib: past, present, and future. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	2
112	Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	0